Latest Regulatory Filings News

Jindalee Lithium has taken another regulatory step by filing an amended Form S-4 with the US SEC, progressing its plan to spin out US lithium assets via US Elemental and list on NASDAQ.

Far East Gold Ltd (ASX: FEG) has explained the delayed filing of a director’s interest change notice, attributing the lag to the off-market takeover bid process by Xingye Gold. The company is reinforcing its disclosure policies to prevent future delays.

Unith Ltd has pushed back the closing date of its non-renounceable entitlement offer to late August, giving shareholders extra time to subscribe for new shares at 0.8 cents each.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.

Jade Gas Holdings has secured regulatory approvals for Mongolia’s first coal bed methane reserves, completed a A$12 million capital raise, and signed a non-binding A$1.1 billion collaboration agreement to fund initial development of its Red Lake gasfield.

Chilwa Minerals has more than doubled its Mpyupyu heavy mineral sands resource to 109.6 million tonnes, defined a maiden niobium-rare earths exploration target at Nakombe, and progressed its planned Nasdaq dual listing with the SEC.

Structural Monitoring Systems Plc (ASX: SMN) reported a milestone FY26 with record revenue of $32.5 million and net profit rising to $1.2 million, driven by strong avionics growth and progressing FAA certification for its CVMTM smart sensor technology.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.